News
-
All treat, no tricks
Friday | Sep 19 2025CUSTOMERS have a chance to win the ultimate Halloween treat haul - a year's supply of Glucojel products.
-
Retinoid action
Friday | Sep 19 2025DIFFERIN Acne Treatment contains the potent retinoid Adapalene to treat and prevent acne, and restore the skin's natural texture and tone.
-
Guild acquires MBA from Strongroom AI
Friday | Sep 19 2025THE Pharmacy Guild of Australia has successfully acquired Member Benefits Australia (MBA) from Strongroom AI (PD breaking news yesterday).
-
Pharmacy board fees for 2025/26
Friday | Sep 19 2025National Boards and the Australian Health Practitioner Regulation Agency (Ahpra) have announced annual registration fees for 2025/26.
-
Dispensary Corner 19 Sep 25
Friday | Sep 19 2025HAVE "skinfluencers" lured you into a "glow trap" and left you with "influencer inflammation"?.
-
Sonictec: One swab, one test, five answers in 15 mins – at home
Friday | Sep 19 2025SONICTEC introduces Australia's first five-in-one rapid antigen test, a revolutionary at-home diagnostic solution that detects five of the most common respiratory viruses simultaneously from a single swab:.
-
PD breaking news – Guild acquires Member Benefits Australia (MBA)
Thursday | Sep 18 2025The Pharmacy Guild of Australia has successfully acquired the entity Member Benefits Australia (MBA) from StrongRoom.
-
Nationally coordinated prescribing closer
Thursday | Sep 18 2025THE Pharmacy Board of Australia announced yesterday that it has begun work to establish an endorsement for scheduled medicines for pharmacists, and when approved will support a consistent, safe and nationally coordinated approach to pharmacist prescribing.
-
Framework to support safer transitions of care
Thursday | Sep 18 2025THE Australian Commission on Safety and Quality in Health Care has released a Medication Management at Transitions of Care Stewardship Framework to support safe and high-quality medication management at transitions of care.
-
Oral GLP-1 safe and effective
Thursday | Sep 18 2025ORAL glucagon-like peptide-1 receptor agonist (GLP-1RA) orforglipron has demonstrated meaningful weight loss and cardiometabolic improvements in patients without diabetes, according to clinical trial findings presented yesterday at the European Association for the Study of Diabetes (EASD) Annual Meeting 2025 in Vienna.
